{"id":"NCT02098395","sponsor":"Novo Nordisk A/S","briefTitle":"The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes","officialTitle":"A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2015-04","completion":"2015-04","firstPosted":"2014-03-28","resultsPosted":"2016-06-03","lastUpdate":"2017-02-09"},"enrollment":835,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"liraglutide","otherNames":[]},{"type":"DRUG","name":"liraglutide","otherNames":[]},{"type":"DRUG","name":"liraglutide","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Liraglutide 1.8 mg + insulin","type":"EXPERIMENTAL"},{"label":"Liraglutide 1.2 mg + insulin","type":"EXPERIMENTAL"},{"label":"Liraglutide 0.6 mg + insulin","type":"EXPERIMENTAL"},{"label":"Liraglutide placebo 0.3 ml + insulin","type":"PLACEBO_COMPARATOR"},{"label":"Liraglutide placebo 0.2 ml + insulin","type":"PLACEBO_COMPARATOR"},{"label":"Liraglutide placebo 0.1 ml + insulin","type":"PLACEBO_COMPARATOR"}],"summary":"This trial is conducted in Africa, Europe and North America. The purpose of the trial is to investigate the efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes.","primaryOutcome":{"measure":"Change From Baseline in Glycosylated Haemoglobin (HbA1c)","timeFrame":"Week 0, Week 26","effectByArm":[{"arm":"Liraglutide 0.6 mg","deltaMin":-0.23,"sd":0.744},{"arm":"Liraglutide 1.2 mg","deltaMin":-0.23,"sd":0.731},{"arm":"Liraglutide 1.8 mg","deltaMin":-0.32,"sd":0.73},{"arm":"Liraglutide Placebo","deltaMin":0.01,"sd":0.674}],"pValues":[{"comp":"OG002 vs OG003","p":"< 0.0001"},{"comp":"OG001 vs OG003","p":"= 0.0021"},{"comp":"OG000 vs OG003","p":"= 0.0011"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":120,"countries":["United States","Austria","Belgium","Bulgaria","Canada","Denmark","Finland","France","Italy","Netherlands","South Africa","Spain","Sweden"]},"refs":{"pmids":["27493132","27493232","39717993","34463425"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":211},"commonTop":["Nausea","Nasopharyngitis","Decreased appetite","Headache","Vomiting"]}}